The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alternating neoadjuvant gemcitabine-nab-paclitaxel (GnP) and nal-irinotecan, 5-fluorouracil and folinic acid (nal-IRI) regimens in resectable (R) and borderline resectable (BR) pancreatic cancer (PC): A pilot study.
 
Vincent Picozzi
Stock and Other Ownership Interests - Amgen; Cigna; Iovance Biotherapeutics; Johnson & Johnson; Lilly; McKesson; Merck; Thermo Fisher Scientific
Consulting or Advisory Role - Revolution Medicines; TriSalus Life Sciences
Research Funding - Abbvie (Inst); AIM ImmunoTech (Inst); Amal Therapeutics (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); FibroGen (Inst); Ipsen (Inst); Merus (Inst); Novocure (Inst); PanTher Therapeutics (Inst); Verastem (Inst)
 
Mannat Sukhija
No Relationships to Disclose
 
Meg Mandelson
No Relationships to Disclose
 
Jessica Lee
Stock and Other Ownership Interests - ImmunityBio
 
Clancy Clark
No Relationships to Disclose
 
Bruce Lin
Research Funding - BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Compass Therapeutics (Inst); Exelixis (Inst); FUJIFILM Toyama Chemistry (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Relay Therapeutics (Inst); Tvardi Therapeutics (Inst); Zymeworks (Inst)